N4P.L

N4 Pharma Plc
N4 Pharma PLC - N4 Pharma Webinar on SRI Collaboration
26th April 2024, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 1231M
N4 Pharma PLC
26 April 2024
 

 

N4 Pharma plc

 ("N4 Pharma" or the "Company")

 

N4 Pharma Webinar on SRI Collaboration

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, will provide a pre-recorded webinar relating to the Company's recent Collaboration Agreement with SRI International Inc. which was announced on 25 April 2024.

 

The webinar will be available for viewing on 7 May 2024 at 10:00 BST, via the Company's Investor Hub: investors.n4pharma.com/welcome.

 

Investors will be notified via email of the presentation if they have signed up to the N4 Pharma Investor Hub in advance, which can be done here: investors.n4pharma.com/auth/signup.

 

Investors are invited to submit questions in advance via N4 Pharma's Investor Hub, and CEO Nigel Theobald will address as many as possible. Register and submit questions at: investors.n4pharma.com

 

 

 

For more information please contact:

 

N4 Pharma plc

Nigel Theobald, CEO

Luke Cairns, Executive Director

investors.n4pharma.com

 

SP Angel Corporate Finance LLP

Nominated Adviser and Joint Broker

Matthew Johnson/Caroline Rowe/Kasia Brzozowska (Corporate Finance)

Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)

Tel: +44(0)20 3470 0470

InvestorHub

Engage with us directly at N4 Pharma Investor Hub

Sign up at investors.n4pharma.com

 

https://investors.n4pharma.com/link/4PKgJP

 

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec®.

 

N4 Pharma's business model is to partner with companies developing novel antigens in these fields to use Nuvec® as the delivery vehicle for these antigens. As these products progress through pre‐clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.

 

For further information on the Company visit www.n4pharma.com or sign up at www.investors.n4pharma.com.

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAUVAURSAUSUUR]]>
TwitterFacebookLinkedIn